# Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use

> **NCT05342493** · — · RECRUITING · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 1000 (estimated)

## Conditions studied

- Migraine Disorders

## Interventions

- **DRUG:** Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution

## Key facts

- **NCT ID:** NCT05342493
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-20
- **Primary completion:** 2026-09-30
- **Final completion:** 2029-06-22
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05342493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05342493, "Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT05342493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*